Literature DB >> 1348799

Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis.

C A Hunter1, F W Jennings, J H Adams, M Murray, P G Kennedy.   

Abstract

The treatment of late-stage African sleeping sickness in man is often complicated by a post-treatment reactive encephalopathy. The bases of this pathological reaction was investigated in a mouse model of African trypanosomiasis. Subcurative treatment with diminazene aceturate, which did not clear parasites from the central nervous system, resulted in a post-treatment meningoencephalitis similar to that seen in man. By contrast, a curative regimen of melaminylthioarsenite and 5-nitroimidazole, which cleared parasites from the central nervous system, did not cause any pathological reaction in the mice. This result indicates that subcurative treatment leads to the development of the post-treatment encephalopathy. Evidence that this may also be the case in man was provided by the detection of trypanosome DNA with the polymerase chain reaction in the brains of 9 patients who had died as the result of a post-treatment reaction. Our findings suggest that more aggressive treatment regimens, which ensure the elimination of trypanosomes from the central nervous system, may prevent post-treatment reactions in patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348799     DOI: 10.1016/0140-6736(92)91531-c

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Human African trypanosomiasis of the CNS: current issues and challenges.

Authors:  Peter G E Kennedy
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Erythrina abyssinica prevents meningoencephalitis in chronic Trypanosoma brucei brucei mouse model.

Authors:  Johnson Nasimolo; Stephen Gitahi Kiama; Peter Karuri Gathumbi; Andrew Ndegwa Makanya; John Maina Kagira
Journal:  Metab Brain Dis       Date:  2014-01-23       Impact factor: 3.584

3.  My life as a clinician-scientist: trying to bridge the perceived gap between medicine and science.

Authors:  Peter G E Kennedy
Journal:  DNA Cell Biol       Date:  2015-03-31       Impact factor: 3.311

4.  A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei.

Authors:  P G Kennedy; J Rodgers; F W Jennings; M Murray; S E Leeman; J M Burke
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Detection of Trypanosoma brucei spp. in human blood by a nonradioactive branched DNA-based technique.

Authors:  E Harris; J Detmer; J Dungan; F Doua; T White; J A Kolberg; M S Urdea; N Agabian
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

Review 6.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Neurological trypanosomiasis in quinapyramine sulfate-treated horses--a breach of the blood-brain barrier?

Authors:  Muthusamy Ranjithkumar; Buddhi Chandrasekaran Saravanan; Suresh Chandra Yadav; Rajender Kumar; Rajendra Singh; Sahadeb Dey
Journal:  Trop Anim Health Prod       Date:  2013-11-06       Impact factor: 1.559

Review 8.  Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.

Authors:  Andrew Jonathan Nok
Journal:  Parasitol Res       Date:  2003-01-31       Impact factor: 2.289

9.  Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis.

Authors:  Jean Rodgers; Amy Jones; Stéphane Gibaud; Barbara Bradley; Christopher McCabe; Michael P Barrett; George Gettinby; Peter G E Kennedy
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

Review 10.  Generation of neuroinflammation in human African trypanosomiasis.

Authors:  Jean Rodgers; Israel Steiner; Peter G E Kennedy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.